Sensus Healthcare, Inc. (SRTS)
Nasdaq · Healthcare · Medical Devices
$2.92−2.01%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $48.1M
- 52-week range
- $2.66 – $5.49
- 52-week change
- −16.06%
- EPS (trailing)
- −$0.94
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $27.5M (−34.26%)
- Net income
- −$7.7M
- Operating margin
- −37.5%
- Diluted EPS
- −$0.47
- Free cash flow
- $330K
From the company’s annual report on SEC EDGAR.
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles.
Headquarters: Boca Raton, United States · 60 employees · sensushealthcare.com